NASDAQ:PEPG PepGen (PEPG) Stock Price, News & Analysis → get a piece of the profit from this land (From True Market Insiders) (Ad) Free PEPG Stock Alerts $13.16 -0.49 (-3.59%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$13.16▼$13.9050-Day Range$10.53▼$15.4452-Week Range$3.72▼$17.51Volume41,346 shsAverage Volume58,311 shsMarket Capitalization$426.65 millionP/E RatioN/ADividend YieldN/APrice Target$24.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get PepGen alerts: Email Address PepGen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside87.4% Upside$24.67 Price TargetShort InterestBearish1.66% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 29 Articles This WeekInsider TradingSelling Shares$134,100 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.96) to ($2.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.05 out of 5 starsMedical Sector603rd out of 919 stocksPharmaceutical Preparations Industry283rd out of 422 stocks 3.5 Analyst's Opinion Consensus RatingPepGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePepGen has only been the subject of 2 research reports in the past 90 days.Read more about PepGen's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.66% of the float of PepGen has been sold short.Short Interest Ratio / Days to CoverPepGen has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in PepGen has recently increased by 33.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPepGen does not currently pay a dividend.Dividend GrowthPepGen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PEPG. Previous Next 2.5 News and Social Media Coverage News SentimentPepGen has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for PepGen this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added PepGen to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PepGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $134,100.00 in company stock.Percentage Held by InsidersOnly 3.97% of the stock of PepGen is held by insiders.Percentage Held by Institutions58.01% of the stock of PepGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PepGen's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PepGen are expected to grow in the coming year, from ($2.96) to ($2.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PepGen is -4.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PepGen is -4.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPepGen has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about PepGen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. About PepGen Stock (NASDAQ:PEPG)PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.Read More PEPG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PEPG Stock News HeadlinesMay 18 at 10:19 AM | insidertrades.comInsider Selling: PepGen Inc. (NASDAQ:PEPG) SVP Sells 10,000 Shares of StockMay 18 at 1:47 AM | americanbankingnews.comQ2 2024 Earnings Estimate for PepGen Inc. (NASDAQ:PEPG) Issued By WedbushMay 18 at 1:47 AM | americanbankingnews.comHC Wainwright Analysts Reduce Earnings Estimates for PepGen Inc. (NASDAQ:PEPG)May 18 at 1:47 AM | americanbankingnews.comBrokers Offer Predictions for PepGen Inc.'s Q2 2024 Earnings (NASDAQ:PEPG)May 17 at 5:48 AM | americanbankingnews.comPepGen Inc. (NASDAQ:PEPG) Expected to Earn FY2028 Earnings of $0.88 Per ShareMay 17 at 5:06 AM | americanbankingnews.comPepGen Inc. (NASDAQ:PEPG) to Post Q1 2025 Earnings of ($0.67) Per Share, Wedbush ForecastsMay 15 at 5:23 PM | markets.businessinsider.comBuy Rating on PepGen Inc. Backed by PGN-EDO51’s Efficacy and Safety ProfileMay 14, 2024 | msn.comPEPG Stock Earnings: PepGen Beats EPS for Q1 2024May 14, 2024 | globenewswire.comPepGen Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 9, 2024 | msn.comHHS panel to vote in Nov. on DMD screening for newbornsMay 2, 2024 | markets.businessinsider.comBuy Rating on Sarepta Therapeutics Backed by Elevidys’s Market Expansion and FDA Approval ProspectsApril 26, 2024 | markets.businessinsider.comOptimistic Outperform Rating on Sarepta Therapeutics Amid Strong Elevidys Demand and Potential Label ExpansionApril 12, 2024 | insidermonkey.comHedge Fund and Insider Trading News: ExodusPoint Capital Management, Bridgewater Associates, Glenview Capital Management, PepGen Inc. (PEPG), HCI Group Inc (HCI), and MoreMarch 13, 2024 | marketwatch.comPepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease DesignationsMarch 13, 2024 | globenewswire.comPepGen to Participate in Upcoming Investor ConferencesMarch 13, 2024 | markets.businessinsider.comPepGen Secures FDA's Orphan Drug, Rare Pediatric Disease Designations For PGN-EDO51March 13, 2024 | globenewswire.comPepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyMarch 12, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on PepGen Inc. (PEPG)March 9, 2024 | seekingalpha.comPepGen, Inc. (PEPG) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | investorplace.comPEPG Stock Earnings: PepGen Beats EPS for Q4 2023March 6, 2024 | investing.comPepGen's DMD therapy advances to phase 2 trial in the UKMarch 6, 2024 | globenewswire.comPepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsMarch 4, 2024 | globenewswire.comPepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyFebruary 21, 2024 | msn.comFDA grants fast track to PepGen’s DM1 treatmentFebruary 20, 2024 | markets.businessinsider.comPepGen Receives U.S. FDA Fast Track Designation For PGN-EDODM1 For The Treatment Of DM1See More Headlines Receive PEPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PepGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today5/18/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PEPG CUSIPN/A CIK1835597 Webwww.pepgen.com Phone781-797-0979FaxN/AEmployees64Year FoundedN/APrice Target and Rating Average Stock Price Target$24.67 High Stock Price Target$28.00 Low Stock Price Target$20.00 Potential Upside/Downside+87.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.32% Return on Assets-46.14% Debt Debt-to-Equity RatioN/A Current Ratio15.78 Quick Ratio6.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.52 per share Price / Book2.38Miscellaneous Outstanding Shares32,420,000Free Float31,130,000Market Cap$426.65 million OptionableNot Optionable Beta1.64 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. James G. McArthur Ph.D. (Age 62)President, CEO, Treasurer, Secretary & Director Comp: $834.98kMr. Noel P. Donnelly M.B.A. (Age 54)Chief Financial Officer Comp: $650.17kMr. Niels Svenstrup Ph.D. (Age 54)Senior Vice President of Chemistry, Manufacturing & Control Comp: $455.15kDr. Michael Gait Ph.D.Founder & Scientific Advisory Board MemberMs. Emiko BryantChief of StaffMr. Kyle BreidenstineVP of Finance & ControllerMore ExecutivesKey CompetitorsTheravance BiopharmaNASDAQ:TBPHFulcrum TherapeuticsNASDAQ:FULCCorbus PharmaceuticalsNASDAQ:CRBPBiomea FusionNASDAQ:BMEAAnnexonNASDAQ:ANNXView All CompetitorsInsiders & InstitutionsRA Capital Management L.P.Bought 2,557,593 shares on 5/17/2024Ownership: 32.972%Artal Group S.A.Bought 200,000 shares on 5/17/2024Ownership: 0.617%Niels SvenstrupSold 10,000 sharesTotal: $134,100.00 ($13.41/share)Janus Henderson Group PLCBought 178,438 shares on 5/16/2024Ownership: 3.602%Vanguard Group Inc.Bought 344,266 shares on 5/10/2024Ownership: 2.626%View All Insider TransactionsView All Institutional Transactions PEPG Stock Analysis - Frequently Asked Questions Should I buy or sell PepGen stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PepGen in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PEPG shares. View PEPG analyst ratings or view top-rated stocks. What is PepGen's stock price target for 2024? 2 Wall Street analysts have issued 12 month price targets for PepGen's shares. Their PEPG share price targets range from $20.00 to $28.00. On average, they predict the company's stock price to reach $24.67 in the next twelve months. This suggests a possible upside of 87.4% from the stock's current price. View analysts price targets for PEPG or view top-rated stocks among Wall Street analysts. How have PEPG shares performed in 2024? PepGen's stock was trading at $6.80 at the start of the year. Since then, PEPG stock has increased by 93.5% and is now trading at $13.16. View the best growth stocks for 2024 here. When is PepGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our PEPG earnings forecast. How were PepGen's earnings last quarter? PepGen Inc. (NASDAQ:PEPG) released its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $0.19. What ETFs hold PepGen's stock? ETFs with the largest weight of PepGen (NASDAQ:PEPG) stock in their portfolio include Morningstar US Small Growth (MSGR).iShares Neuroscience and Healthcare ETF (IBRN). When did PepGen IPO? PepGen (PEPG) raised $126 million in an initial public offering on Friday, May 6th 2022. The company issued 9,000,000 shares at $13.00-$15.00 per share. Who are PepGen's major shareholders? PepGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (32.97%), Janus Henderson Group PLC (3.60%), Vanguard Group Inc. (2.63%), Artal Group S.A. (0.62%) and Acadian Asset Management LLC (0.01%). Insiders that own company stock include James G Mcarthur, Jaya Goyal, Niels Svenstrup and Ra Capital Management, LP. View institutional ownership trends. How do I buy shares of PepGen? Shares of PEPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PEPG) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceI’m afraid WWIII is a very real possibility Porter & CompanyProtect Your Bank Account Before It’s Too LateWeiss RatingsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.